Current aspects of the interactions between dementia, the brain renin-angiotensin system and oxidative stress

Şerban, Dragomir Nicolae; Anton, Emil; Chiriță, Roxana; Bild, Veronica; Ciobîcă, Alin; Alexinschi, Ovidiu; Arcan, Oana; Popescu, Radu; Păduraru, Luminiţa; Timofte, Daniel

doi:10.2298/abs140228051s

Cited by 6 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent data extended on the initial antioxidant-based mechanism of polyphenols’ activity by displaying that they are also able to modulate numerous cell-signaling pathways and mediators. These properties stimulated the researchers’ interest in polyphenolic compounds and many studies point out their potential role in preventing and treating a wide range of human pathological conditions related to inflammation and oxidative stress, such as cancer, neurodegenerative and cardiovascular disorders [ 100 , 101 , 102 ]. In clinical trials, curcumin and EGCG confirmed to target Aβ, tau, and transthyretin.…”

Section: Discussionmentioning

confidence: 99%

Secondary Metabolites from Plants Possessing Inhibitory Properties against Beta-Amyloid Aggregation as Revealed by Thioflavin-T Assay and Correlations with Investigations on Transgenic Mouse Models of Alzheimer’s Disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

Alzheimer’s disease is a neurodegenerative disorder for which there is a continuous search of drugs able to reduce or stop the cognitive decline. Beta-amyloid peptides are composed of 40 and 42 amino acids and are considered a major cause of neuronal toxicity. They are prone to aggregation, yielding oligomers and fibrils through the inter-molecular binding between the amino acid sequences (17–42) of multiple amyloid-beta molecules. Additionally, amyloid deposition causes cerebral amyloid angiopathy. The present study aims to identify, in the existing literature, natural plant derived products possessing inhibitory properties against aggregation. The studies searched proved the anti-aggregating effects by the thioflavin T assay and through behavioral, biochemical, and histological analysis carried out upon administration of natural chemical compounds to transgenic mouse models of Alzheimer’s disease. According to our present study results, fifteen secondary metabolites from plants were identified which presented both evidence coming from the thioflavin T assay and transgenic mouse models developing Alzheimer’s disease and six additional metabolites were mentioned due to their inhibitory effects against fibrillogenesis. Among them, epigallocatechin-3-gallate, luteolin, myricetin, and silibinin were proven to lower the aggregation to less than 40%.

show abstract

Section: Discussionmentioning

confidence: 99%

Secondary Metabolites from Plants Possessing Inhibitory Properties against Beta-Amyloid Aggregation as Revealed by Thioflavin-T Assay and Correlations with Investigations on Transgenic Mouse Models of Alzheimer’s Disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The influence of high glucose levels on cognitive impairment was highlighted in the ACCORD-MIND study, which by assessing glycosylated hemoglobin (HbA1c) could detect the negative impact on cognitive tests [ 71 ]. It is possible that chronic exposure of the brain to high glucose levels may hasten cognitive decline, which was observed in post-mortem studies carried out with patients with AD where amyloid plaques and metabolic degradation products associated with hyperglycemia were found [ 72 , 73 ]. Hyperglycemia levels most likely due to poor insulin synthesis could be corrected by using mediational therapies involved in increasing insulin levels.…”

Section: Amyloid Formation As a Common Pathological Feature In Botmentioning

confidence: 99%

Link between Diabetes and Alzheimer’s Disease Due to the Shared Amyloid Aggregation and Deposition Involving Both Neurodegenerative Changes and Neurovascular Damages

Stanciu

Bild

Ababei

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Diabetes and Alzheimer’s disease are two highly prevalent diseases among the aging population and have become major public health concerns in the 21st century, with a significant risk to each other. Both of these diseases are increasingly recognized to be multifactorial conditions. The terms “diabetes type 3” or “brain diabetes” have been proposed in recent years to provide a complete view of the potential common pathogenic mechanisms between these diseases. While insulin resistance or deficiency remains the salient hallmarks of diabetes, cognitive decline and non-cognitive abnormalities such as impairments in visuospatial function, attention, cognitive flexibility, and psychomotor speed are also present. Furthermore, amyloid aggregation and deposition may also be drivers for diabetes pathology. Here, we offer a brief appraisal of social impact and economic burden of these chronic diseases and provide insight into amyloidogenesis through considering recent advances of amyloid-β aggregates on diabetes pathology and islet amyloid polypeptide on Alzheimer’s disease. Exploring the detailed knowledge of molecular interaction between these two amyloidogenic proteins opens new opportunities for therapies and biomarker development.

show abstract

“…SAA, an apo-lipoprotein synthesized by the liver, is an acute phase reactant extensively studied in various acute pathologies in adults (cardiac, renal, degenerative disorders) [ 80 , 81 , 82 , 83 , 84 , 85 ]. Its levels rise early during the inflammatory response up to 1000 times higher than the baseline serum values but are significantly influenced by the patient’s hepatic function and nutritional status.…”

Section: Biomarkers Commonly Used or Under Consideration For Eos Dmentioning

confidence: 99%

Relevance of Biomarkers Currently in Use or Research for Practical Diagnosis Approach of Neonatal Early-Onset Sepsis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Neonatal early-onset sepsis (EOS) is defined as an invasive infection that occurs in the first 72 h of life. The incidence of EOS varies from 0.5–2% live births in developed countries, up to 9.8% live births in low resource settings, generating a high mortality rate, especially in extremely low birth weight neonates. Clinical signs are nonspecific, leading to a late diagnosis and high mortality. Currently, there are several markers used for sepsis evaluation, such as hematological indices, acute phase reactants, cytokines, which by themselves do not show acceptable sensitivity and specificity for the diagnosis of EOS in neonates. Newer and more selective markers have surfaced recently, such as presepsin and endocan, but they are currently only in the experimental research stages. This comprehensive review article is based on the role of biomarkers currently in use or in the research phase from a basic, translational, and clinical viewpoint that helps us to improve the quality of neonatal early-onset sepsis diagnosis and management.

show abstract

Current aspects of the interactions between dementia, the brain renin-angiotensin system and oxidative stress

Cited by 6 publications

References 25 publications

Secondary Metabolites from Plants Possessing Inhibitory Properties against Beta-Amyloid Aggregation as Revealed by Thioflavin-T Assay and Correlations with Investigations on Transgenic Mouse Models of Alzheimer’s Disease

Secondary Metabolites from Plants Possessing Inhibitory Properties against Beta-Amyloid Aggregation as Revealed by Thioflavin-T Assay and Correlations with Investigations on Transgenic Mouse Models of Alzheimer’s Disease

Link between Diabetes and Alzheimer’s Disease Due to the Shared Amyloid Aggregation and Deposition Involving Both Neurodegenerative Changes and Neurovascular Damages

Relevance of Biomarkers Currently in Use or Research for Practical Diagnosis Approach of Neonatal Early-Onset Sepsis

Contact Info

Product

Resources

About